We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Wolff-Parkinson-White Syndrome Anterograde Refractory Period of Accessory Duct (WPW)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00873470
Recruitment Status : Terminated
First Posted : April 1, 2009
Last Update Posted : February 8, 2013
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:

The study consists of the realization of a new esophageal stimulation for patients already stimulated 10 years ago.

The investigators would like to make a long term evaluation of the evolution of anterograde effective refractory period of accessory duct in the WPW syndrome.

This study will be realized by esophageal stimulation.

Condition or disease Intervention/treatment
Wolff-Parkinson-White Syndrome Procedure: esophagal stimulation

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Long Term Evolution of the Anterograde Refractory Period of Accessory Duct in the Wolff-Parkinson-White Syndrome
Study Start Date : February 2009
Primary Completion Date : December 2012
Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Stimulation
All patients included have the stimulation
Procedure: esophagal stimulation
ECG (rest) esophagal stimulation (rest and during effort)

Primary Outcome Measures :
  1. Measurement of effective anterograde refractory period of accessory duct and its evolution for a follow up superior to 10 years [ Time Frame: Day 0 ]

Secondary Outcome Measures :
  1. Triggering a supra-ventricular tachycardia during the stimulation. [ Time Frame: Day 0 ]
  2. Presence of symptoms linked to WPW syndrome during the interval separating the 2 esophageal stimulation. [ Time Frame: Day 0 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 21 < age < 64 years
  • First esophagal stimulation with evaluation of effective anterograde refractory period > 10 years
  • Informed consent signed
  • Diagnosis of Wolff-Parkinson-White syndrome
  • No procedure of ablation of accessory duct

Exclusion Criteria:

  • Ablation of accessory duct
  • Patient with contraindication to esophageal stimulation
  • Patient with contraindication to effort test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00873470

Nantes UH
Nantes, France, 44093
Sponsors and Collaborators
Nantes University Hospital

Responsible Party: Nantes University Hospital
ClinicalTrials.gov Identifier: NCT00873470     History of Changes
Other Study ID Numbers: BRD 08/9-I
First Posted: April 1, 2009    Key Record Dates
Last Update Posted: February 8, 2013
Last Verified: February 2013

Additional relevant MeSH terms:
Wolff-Parkinson-White Syndrome
Pre-Excitation Syndromes
Parkinson Disease
Pathologic Processes
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Congenital Abnormalities